Enabling biomedical technologies for chronic myelogenous leukemia (CML) biomarkers detection

Area of Science:

• Hematology
• Oncology
• Biomedical Engineering

Background:

• Chronic myelogenous leukemia (CML) is a bone marrow cancer originating from hematopoietic stem cells, affecting millions globally.
• Most CML cases (85%) are diagnosed in the chronic phase, often via routine screenings.
• Current diagnostic methods rely on biomarkers like leukocytes, micro-RNAs, and myeloid markers, typically detected through lab-based techniques.

Purpose of the Study:

• To analyze the significance of CML, its symptoms, and diagnostic biomarkers.
• To review current CML detection techniques and their impact on patient survival.
• To explore the potential of microfluidic devices for point-of-care CML diagnosis.

Main Methods:

• Comprehensive literature review on CML diagnosis and treatment.
• Analysis of existing diagnostic technologies (PCR, flow cytometry, genetic testing).
• Evaluation of microfluidic device applications for biomarker detection.

Main Results:

• Early CML detection significantly improves patient survival rates.
• Existing diagnostic tools are effective but limited to laboratory settings due to cost and complexity.
• Microfluidic devices offer a promising avenue for accessible, point-of-care CML diagnostics.

Conclusions:

• Point-of-care testing using microfluidics can enhance early CML detection.
• Developing cost-effective, portable diagnostic tools is key to improving patient outcomes.
• Further research into microfluidic applications for CML biomarker detection is warranted.